Asset Details
Do you wish to reserve the book?
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
Do you wish to request the book?
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
2008
Overview
This study investigated the safety and efficacy of subcutaneous methylnaltrexone, a μ-opioid–receptor antagonist, for treating opioid-induced constipation in patients with advanced illness. Methylnaltrexone rapidly induced laxation without affecting central analgesia or precipitating withdrawal.
This study investigated the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness. Methylnaltrexone rapidly induced laxation without affecting central analgesia or precipitating withdrawal.
Clinicians often use opioids to treat moderate-to-severe pain; however, opioids frequently induce or aggravate constipation. Empirically, laxative therapy may be burdensome and ineffective and result in temporally unpredictable responses. In addition, severe opioid-induced constipation may limit opioid therapy, worsening analgesia. These drawbacks can substantially compromise the quality of life, especially in patients with advanced illness.
Opioid-induced constipation is predominantly mediated by gastrointestinal μ-opioid receptors.
1
,
2
Selective blockade of these peripheral receptors might relieve constipation without compromising centrally mediated effects of opioid analgesia or precipitating withdrawal. N-methylation of the uncharged systemic opioid antagonist, naltrexone,
3
results in a charged derivative, methylnaltrexone, which . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Analgesics, Opioid - adverse effects
/ Biological and medical sciences
/ Constipation - chemically induced
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Male
/ Naltrexone - adverse effects
/ Naltrexone - analogs & derivatives
/ Naltrexone - therapeutic use
/ Narcotic Antagonists - adverse effects
/ Narcotic Antagonists - therapeutic use
/ Quaternary Ammonium Compounds - adverse effects
/ Quaternary Ammonium Compounds - therapeutic use
